• Endovia Health Sciences secured an FDA investigational new animal drug file for its CannEpil veterinary program, opening formal regulatory review.
• The FDA Center for Veterinary Medicine assigned INAD File No. 14145, a first milestone under its collaboration with Lupvindol Biosciences.
• Initial development targets cancer-related pain in dogs, with the company pursuing MUMS designation and the FDA conditional approval pathway.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Endovia Health Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001731122-26-001144), on August 25, 2026, and is solely responsible for the information contained therein.